NCT05845424View on ClinicalTrials.gov

High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium

PHASE4RecruitingINTERVENTIONAL
Enrollment

6,000

Participants

Timeline

Start Date

July 3, 2023

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2030

Conditions
Coronary Artery CalcificationMetabolic SyndromeDyslipidemias
Interventions
DRUG

Guideline directed statin therapy

At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk

DRUG

High intensity statin plus ezetimibe therapy

Rosuvastatin 20 mg + Ezetimibe 10 mg

Trial Locations (1)

06351

RECRUITING

SamsungMedicalCenter, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER